Irwin Law1, Katherine Floyd1. 1. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
Abstract
OBJECTIVE AND METHODS: Worldwide, tuberculosis (TB) is the leading cause of death from a single infectious agent. In many countries, national TB prevalence surveys are the only way to reliably measure the burden of TB disease and can also provide other evidence to inform national efforts to improve TB detection and treatment. Our objective was to synthesise the results and lessons learned from national surveys completed in Africa between 2008 and 2016, to complement a previous review for Asia. RESULTS: Twelve surveys completed in Africa were identified: Ethiopia (2010-2011), Gambia (2011-2013), Ghana (2013), Kenya (2015-2016), Malawi (2013-2014), Nigeria (2012), Rwanda (2012), Sudan (2013-2014), Tanzania (2011-2012), Uganda (2014-2015), Zambia (2013-2014) and Zimbabwe (2014). The eligible population in all surveys was people aged ≥15 years who met residency criteria. In total 588 105 individuals participated, equivalent to 82% (range 57-96%) of those eligible. The prevalence of bacteriologically confirmed pulmonary TB disease in those ≥15 years varied from 119 (95% CI 79-160) per 100 000 population in Rwanda and 638 (95% CI 502-774) per 100 000 population in Zambia. The male:female ratio was 2.0 overall, ranging from 1.2 (Ethiopia) to 4.1 (Uganda). Prevalence per 100 000 population generally increased with age, but the absolute number of cases was usually highest among those aged 35-44 years. Of identified TB cases, 44% (95% CI 40-49) did not report TB symptoms during screening and were only identified as eligible for diagnostic testing due to an abnormal chest X-ray. The overall ratio of prevalence to case notifications was 2.5 (95% CI 1.8-3.2) and was consistently higher for men than women. Many participants who did report TB symptoms had not sought care; those that had were more likely to seek care in a public health facility. HIV prevalence was systematically lower among prevalent cases than officially notified TB patients with an overall ratio of 0.5 (95% CI 0.3-0.7). The two main study limitations were that none of the surveys included people <15 years, and 5 of 12 surveys did not have data on HIV status. CONCLUSIONS: National TB prevalence surveys implemented in Africa between 2010 and 2016 have contributed substantial new evidence about the burden of TB disease, its distribution by age and sex, and gaps in TB detection and treatment. Policies and practices to improve access to health services and reduce under-reporting of detected TB cases are needed, especially among men. All surveys provide a valuable baseline for future assessment of trends in TB disease burden.
OBJECTIVE AND METHODS: Worldwide, tuberculosis (TB) is the leading cause of death from a single infectious agent. In many countries, national TB prevalence surveys are the only way to reliably measure the burden of TB disease and can also provide other evidence to inform national efforts to improve TB detection and treatment. Our objective was to synthesise the results and lessons learned from national surveys completed in Africa between 2008 and 2016, to complement a previous review for Asia. RESULTS: Twelve surveys completed in Africa were identified: Ethiopia (2010-2011), Gambia (2011-2013), Ghana (2013), Kenya (2015-2016), Malawi (2013-2014), Nigeria (2012), Rwanda (2012), Sudan (2013-2014), Tanzania (2011-2012), Uganda (2014-2015), Zambia (2013-2014) and Zimbabwe (2014). The eligible population in all surveys was people aged ≥15 years who met residency criteria. In total 588 105 individuals participated, equivalent to 82% (range 57-96%) of those eligible. The prevalence of bacteriologically confirmed pulmonary TB disease in those ≥15 years varied from 119 (95% CI 79-160) per 100 000 population in Rwanda and 638 (95% CI 502-774) per 100 000 population in Zambia. The male:female ratio was 2.0 overall, ranging from 1.2 (Ethiopia) to 4.1 (Uganda). Prevalence per 100 000 population generally increased with age, but the absolute number of cases was usually highest among those aged 35-44 years. Of identified TB cases, 44% (95% CI 40-49) did not report TB symptoms during screening and were only identified as eligible for diagnostic testing due to an abnormal chest X-ray. The overall ratio of prevalence to case notifications was 2.5 (95% CI 1.8-3.2) and was consistently higher for men than women. Many participants who did report TB symptoms had not sought care; those that had were more likely to seek care in a public health facility. HIV prevalence was systematically lower among prevalent cases than officially notified TB patients with an overall ratio of 0.5 (95% CI 0.3-0.7). The two main study limitations were that none of the surveys included people <15 years, and 5 of 12 surveys did not have data on HIV status. CONCLUSIONS: National TB prevalence surveys implemented in Africa between 2010 and 2016 have contributed substantial new evidence about the burden of TB disease, its distribution by age and sex, and gaps in TB detection and treatment. Policies and practices to improve access to health services and reduce under-reporting of detected TB cases are needed, especially among men. All surveys provide a valuable baseline for future assessment of trends in TB disease burden.
Authors: Anna H van't Hoog; Kayla F Laserson; Willie A Githui; Helen K Meme; Janet A Agaya; Lazarus O Odeny; Benson G Muchiri; Barbara J Marston; Kevin M DeCock; Martien W Borgdorff Journal: Am J Respir Crit Care Med Date: 2011-01-14 Impact factor: 21.405
Authors: M Senkoro; S G Hinderaker; S G Mfinanga; N Range; D V Kamara; S Egwaga; F van Leth Journal: Int J Tuberc Lung Dis Date: 2015-06 Impact factor: 2.373
Authors: F Bonsu; K K Addo; Z Alebachew; J Gyapong; A Badu-Peprah; R Gockah; N N Hanson-Nortey; I Law; M Tadolini; I Onozaki; C Sismanidis; E Owusu-Dabo Journal: Int J Tuberc Lung Dis Date: 2020-03-01 Impact factor: 2.373
Authors: A H Kebede; Z Alebachew; F Tsegaye; E Lemma; A Abebe; M Agonafir; A J Kebede; D Demissie; F Girmachew; Z Yaregal; F Dana; M Getahun; Y Fiseha; A Meaza; N Dirse; H Timimi; C Sismanidis; M Tadolini; I Onozaki Journal: Int J Tuberc Lung Dis Date: 2014-06 Impact factor: 2.373
Authors: Ifedayo Mo Adetifa; Lindsay Kendall; Adedapo Bashorun; Christopher Linda; Semeeh Omoleke; David Jeffries; Rahmatulai Maane; Beatrice Dei Alorse; William Dei Alorse; Catherine Bi Okoi; Kodjovi D Mlaga; Ma Ansu Kinteh; Simon Donkor; Bouke C de Jong; Martin Antonio; Umberto d'Alessandro Journal: Bull World Health Organ Date: 2016-04-21 Impact factor: 9.408
Authors: Patrick Migambi; Michel Gasana; Claude Bernard Uwizeye; Eliane Kamanzi; Vedaste Ndahindwa; Nico Kalisvaart; Eveline Klinkenberg Journal: PLoS One Date: 2020-04-23 Impact factor: 3.240
Authors: Katherine C Horton; Peter MacPherson; Rein M G J Houben; Richard G White; Elizabeth L Corbett Journal: PLoS Med Date: 2016-09-06 Impact factor: 11.069
Authors: M Chipinduro; C Timire; J Chirenda; R Matambo; E Munemo; B Makamure; A F Nhidza; W Tinago; V Chikwasha; M Ngwenya; J Mutsvangwa; J Z Metcalfe; C Sandy Journal: Int J Tuberc Lung Dis Date: 2022-01-01 Impact factor: 2.373
Authors: Sian Floyd; Eveline Klinkenberg; Petra de Haas; Barry Kosloff; Thomas Gachie; Pete J Dodd; Maria Ruperez; Chali Wapamesa; Michael J Burnett; Nico Kalisvaart; Redwaan Vermaak; Tila Mainga; Albertus Schaap; Sarah Fidler; Linda Mureithi; Kwame Shanaube; Richard Hayes; Helen Ayles Journal: BMJ Open Date: 2022-06-16 Impact factor: 3.006
Authors: Helena R A Feasey; Elizabeth L Corbett; Marriott Nliwasa; Luke Mair; Titus H Divala; Wala Kamchedzera; Mc Ewen Khundi; Helen E D Burchett; Emily L Webb; Hendramoorthy Maheswaran; S Bertel Squire; Peter MacPherson Journal: BMC Infect Dis Date: 2021-02-15 Impact factor: 3.090
Authors: Joanitah Nalunjogi; Frank Mugabe; Irene Najjingo; Pastan Lusiba; Francis Olweny; Joseph Mubiru; Edward Kayongo; Rogers Sekibira; Achilles Katamba; Bruce Kirenga Journal: Tuberc Res Treat Date: 2021-03-19
Authors: Simon C Mendelsohn; Stanley Kimbung Mbandi; Andrew Fiore-Gartland; Adam Penn-Nicholson; Munyaradzi Musvosvi; Humphrey Mulenga; Michelle Fisher; Katie Hadley; Mzwandile Erasmus; Onke Nombida; Michèle Tameris; Gerhard Walzl; Kogieleum Naidoo; Gavin Churchyard; Mark Hatherill; Thomas J Scriba Journal: Commun Med (Lond) Date: 2022-03-10
Authors: R Abeid; C Mergenthaler; V Muzuka; A Goodluck; T Nkwabi; J Bigio; Aguilera Vasquez N; T Pande; F Haraka; J Creswell; T Rahman; M Straetemans Journal: J Trop Med Date: 2022-03-12
Authors: Simon C Mendelsohn; Andrew Fiore-Gartland; Denis Awany; Humphrey Mulenga; Stanley Kimbung Mbandi; Michèle Tameris; Gerhard Walzl; Kogieleum Naidoo; Gavin Churchyard; Thomas J Scriba; Mark Hatherill Journal: EClinicalMedicine Date: 2022-03-05